UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.755

Sortiert nach

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

Cancer, 2021-08, Vol.127 (16), p.3019-3028

2021

Volltextzugriff (PDF)

Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B

Cancer, 2024-05, Vol.130 (9), p.1693-1701

2024

Volltextzugriff (PDF)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Cancer medicine (Malden, MA), 2022-08, Vol.11 (15), p.2944-2956

2022

Volltextzugriff (PDF)

Prognostic Value of the Neutrophil-to-Lymphocyte Ratio before and after Radiotherapy for Anaplastic Thyroid Carcinoma

Cancers, 2021-04, Vol.13 (8), p.1913

2021

Volltextzugriff (PDF)

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Nature communications, 2020-05, Vol.11 (1), p.2285-2285, Article 2285

2020

Volltextzugriff (PDF)

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1916-1928

2022

Volltextzugriff (PDF)

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2020-08, Vol.146, p.23-29

2020

Volltextzugriff (PDF)

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Journal of clinical oncology, 2024-04, Vol.42 (11), p.1241

2024

Volltextzugriff (PDF)

Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control

Scientific reports, 2024-06, Vol.14 (1), p.14659-9, Article 14659

2024

Volltextzugriff (PDF)

Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

PloS one, 2022-10, Vol.17 (10), p.e0274830-e0274830

2022

Volltextzugriff (PDF)

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma

European journal of cancer (1990), 2020-06, Vol.132, p.150-158

2020

Volltextzugriff (PDF)

Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect

Cancer Immunology, Immunotherapy, 2021-05, Vol.70 (5), p.1203-1211

2021

Volltextzugriff (PDF)

Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

PloS one, 2022-10, Vol.17 (10), p.e0274830

2022

Volltextzugriff (PDF)

Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2023-02, Vol.115 (2), p.464-475

2023

Volltextzugriff (PDF)

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2023-09, Vol.18 (9), p.1199-1208

2023

Volltextzugriff (PDF)

Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy

International journal of radiation oncology, biology, physics, 2022-06, Vol.113 (2), p.415

2022

Volltextzugriff (PDF)

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Journal of thoracic oncology, 2023-07, Vol.18 (7), p.896-906

2023

Volltextzugriff (PDF)

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome

The Korean Journal of Internal Medicine, 2021, 36(2), , pp.413-423

2021

Volltextzugriff (PDF)

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

BMC cancer, 2020-08, Vol.20 (1), p.727-727, Article 727

2020

Volltextzugriff (PDF)

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

BMC ophthalmology, 2020-01, Vol.20 (1), p.19-13, Article 19

2020

Volltextzugriff (PDF)

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

Cancer medicine (Malden, MA), 2023-08, Vol.12 (15), p.15788-15796

2023

Volltextzugriff (PDF)

Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor -Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine Kinase Inhibitor: A Real-World External Comparator Study

Cancers, 2024-06, Vol.16 (12), p.2169

2024

Volltextzugriff (PDF)

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Cancers, 2023-11, Vol.15 (22), p.5450

2023

Volltextzugriff (PDF)

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

Cancer medicine (Malden, MA), 2020-04, Vol.9 (7), p.2352-2362

2020

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

대한신경외과학회지, 2021, 64(2), , pp.271-281

2021

Volltextzugriff (PDF)

1 – 25 von 1.755

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.568)
Mit Volltextzugriff
(1.669)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(21)
... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Prognostic Value of the Neutrophil-to-Lymphocyte Ratio before and after Radiotherapy for Anaplastic Thyroid Carcinoma

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control

Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma

Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect

Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer

Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor -Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine Kinase Inhibitor: A Real-World External Comparator Study

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

Suchergebnisse filtern